Month: September 2026

– Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months –

– Data continued to support improvement at 6 months in video hand opening time (vHOT) as an early indicator of clinical benefit with z-basivarsen in DM1 –

– Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC), with a primary endpoint of change from baseline in vHOT at 6 months, intended to support a potential submission for U.S. Accelerated Approval in Q3 2027 –

– The mean baseline vHOT in the ACHIEVE REC is 8.3 seconds –

WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced additional one-year efficacy data from the MAD portion of its ongoing Phase 1/2 ACHIEVE clinical trial of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) for DM1, showing functional improvement across multiple measures. These data are being presented at the 31^st Annual International Congress of the World Muscle Society (WMS) being held September 29, 2026, through October 3, 2026, virtually and in Hiroshima, Japan, as well as the 2026 Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) being held September 29, 2026, through October 2, 2026, virtually and in Orlando, Florida.

“This week we are presenting data at 6 and 12 months from a larger pooled dose group of participants from ACHIEVE, which further support our confidence in the results we have previously presented from smaller individual dose cohorts,” said Doug Kerr, M.D., Ph.D., chief medical officer of Dyne. “In addition, for the first time, we are showing functional improvement across multiple measures compared to a matched natural history cohort, not just compared to placebo and compared to baseline. We attribute these results to the differentiated properties of our FORCE platform and z-basivarsen, which is designed to correct the core underlying splicing abnormalities in DM1 by delivering a targeted therapeutic payload to the nucleus in both muscle and the CNS. We aim to confirm these findings through both the ACHIEVE REC and the Phase 3 HARMONIA study, which is currently recruiting participants at over 35 active global sites.”

The analyses being presented at WMS and AANEM were designed to evaluate whether a larger treated group showed the same positive efficacy trends previously observed in a smaller cohort of participants receiving the registrational dose of 6.8 mg/kg Q8W (N=6). Data from a pooled dose group of participants (N=25-26) from the 3.4 mg/kg Q4W, 5.4 mg/kg Q8W and 6.8 mg/kg Q8W cohorts of the MAD portion of the ACHIEVE trial, including participants originally assigned to the placebo group (re-baselined to the visit prior to their first active dose), were assessed through 12 months of treatment. 

The pooled dose group includes a mixture of dose exposures and does not reflect the effect of maintaining the registrational dose of 6.8 mg/kg for the entire treatment duration, as only 8 of 26 participants in the pooled dose group received the registrational dose for the full 12 months analyzed and most did not receive the registrational dose during this timeframe.

At 12 months, these data were compared to a cohort of participants (N=41-46) from the ongoing END-DM1 natural history study who were propensity-matched to the ACHIEVE pooled dose group.   

The new results to be presented at WMS and AANEM include:

• Myotonia: Sustained improvement from baseline in hand myotonia, as measured by vHOT. The pooled dose group had a mean baseline vHOT of 8.2 seconds, which decreased by 3.2 seconds at 6 months (standard deviation of change from baseline: 3.5 seconds). This is compared to an increase of 0.4 seconds in the placebo group from the ACHIEVE MAD at 6 months (N=14), representing a 3.6 second relative improvement. The change from baseline in vHOT at 6 months is the primary endpoint of the ACHIEVE REC, from which topline data are expected in Q1 2027 to support a potential Biologics License Application (BLA) submission for U.S. Accelerated Approval in Q3 2027.
   
• Function: Sustained improvement from baseline in function, as assessed by the 5 times sit to stand (5xSTS) test and the 10-meter walk/run (10MWR) test. In the pooled dose group at 12 months, participants improved on 5xSTS by 1.2 seconds and on 10MWR by 0.3 seconds relative to baseline, showing a divergence from the matched natural history cohort on 10MWR. 5xSTS was not included in the END-DM1 natural history study, so no comparisons could be made. The change from baseline in 5xSTS at 12 months is the primary endpoint of the ongoing global Phase 3 HARMONIA clinical trial, which is intended to serve as a confirmatory trial for traditional approval in the U.S. and support ex-U.S. marketing applications.  
   
• Strength: Sustained improvement from baseline on muscle strength as assessed by the quantitative muscle testing (QMT) total score and the individual QMT hand grip score. In the pooled dose group at 12 months, participants improved on both QMT total and hand grip by 4.8% predicted relative to baseline, showing a divergence from the matched natural history cohort on both measures.
   
• Patient Reported Outcomes: Sustained improvement from baseline in the Myotonic Dystrophy Health Index (MDHI) patient reported outcome measure, including in 6 subscales assessing central nervous system (CNS) disease manifestations (cognitive impairment, sleep disturbances, fatigue, communication, emotional issues and pain). In the pooled dose group at 12 months, participants improved on the MDHI total score by 25.2% relative to baseline, showing a divergence from an unmatched END-DM1 natural history cohort (N=410).
   
• Safety and Tolerability: Updated safety and tolerability data from participants initially enrolled in the MAD portion of the ACHIEVE trial. Z-basivarsen continued to demonstrate a favorable safety profile, and no related serious treatment emergent adverse events were identified.¹

These data will be presented in an oral presentation at WMS titled “Long-term functional improvement with zeleciment basivarsen in the Phase 1/2 ACHIEVE trial.” The slides for this presentation are now available in the Scientific Publications & Presentations section of Dyne’s website. Additionally, these data will be presented in a poster presentation at AANEM titled “Zeleciment basivarsen targets the underlying cause of myotonic dystrophy type 1 to enable functional improvement in the Phase 1/2 ACHIEVE trial,” which will be available in the Scientific Publications & Presentations section of Dyne’s website on Wednesday, September 30 at 6:15 p.m. ET.

Baseline vHOT of the ACHIEVE Registrational Expansion Cohort (REC)

The mean baseline value for vHOT of the 71 participants enrolled in the ACHIEVE REC is 8.3 seconds (standard deviation at baseline: 6.0 seconds). These baseline data remain blinded to treatment assignment. Topline data from the ACHIEVE REC, which is intended to support a potential application for U.S. Accelerated Approval, are planned for Q1 2027.

About the ACHIEVE Trial

ACHIEVE is a global, randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial evaluating the safety, tolerability and efficacy of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in patients with myotonic dystrophy type 1 (DM1). The multiple ascending dose (MAD) portion of the study resulted in the selection of a registrational dose and regimen of 6.8 mg/kg z-basivarsen administered every eight weeks. A registrational expansion cohort to support potential regulatory submissions, including Accelerated Approval in the U.S., is fully enrolled. The primary endpoint for this cohort is the change from baseline in middle finger myotonia as measured by video hand opening time (vHOT) at 6 months, compared to placebo. For more information on the ACHIEVE trial, visit www.clinicaltrials.gov (NCT05481879) and euclinicaltrials.eu (EUCT2023-510353-42-00).

About zeleciment basivarsen (z-basivarsen, also known as DYNE-101) 

Z-basivarsen is an investigational therapeutic being evaluated in the fully enrolled global Phase 1/2 ACHIEVE clinical trial and the global confirmatory Phase 3 HARMONIA clinical trial for people living with DM1. Z-basivarsen consists of an antisense oligonucleotide (ASO) conjugated to an antigen-binding fragment (Fab) that binds to the transferrin receptor 1 (TfR1) to enable delivery to muscle and the central nervous system. It is designed to deliver functional improvement in individuals living with DM1 by reducing toxic nuclear DMPK RNA to release splicing proteins and allow normal mRNA processing. Z-basivarsen has been granted Breakthrough Therapy, Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA), as well as Orphan Drug designation from the European Medicines Agency (EMA) and the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of DM1.

About Myotonic Dystrophy Type 1 (DM1) 

Myotonic dystrophy type 1 (DM1) is a rare, progressive, genetic neuromuscular disease with high morbidity and early mortality. DM1 affects ~40,000 people in the U.S. and ~55,000 people in the EU. The severity of symptoms and rate of progression vary. Symptoms can begin at any point in an affected person’s life, depending on the DM1 subtype. Adult-onset DM1 symptoms typically appear between 20 to 40 years of age. DM1 is caused by mutations in the DMPK gene, leading to a widespread disruption of RNA splicing, known as spliceopathy, which drives the multi-system manifestations of the disease. People experience a broad spectrum of symptoms, including: muscle weakness throughout the body, myotonia or difficulty relaxing muscles, excessive daytime sleepiness, fatigue, dysregulated sleep, cognitive impairments, cardiac arrhythmias, respiratory issues and gastrointestinal dysfunction. Although the genetic cause of DM1 is well understood, there are currently no approved disease-modifying treatments for DM1.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the clinical potential of zeleciment basivarsen (“z-basivarsen,” also known as DYNE-101) and its potential to mitigate central nervous system-related manifestations of myotonic dystrophy type 1, expectations regarding the timing and outcome of data from clinical trials, expectations regarding the timing and outcome of submissions to and interactions with global regulatory authorities, the availability of accelerated approval pathways for z-basivarsen, and the potential of video hand opening time to serve as an intermediate clinical endpoint for U.S. accelerated approval, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” ”might,” ”objective,” ”ongoing,” ”plan,” ”predict,” ”project,” ”potential,” ”should,” ”will” or ”would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne’s ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials; uncertainties as to the FDA’s and other regulatory authorities’ interpretation of the data from Dyne’s clinical trials and acceptance of Dyne’s clinical programs and the regulatory approval process; whether Dyne’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.

^1. Z-basivarsen safety data as of April 20, 2026.

Contacts:

Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
media@dyne-tx.com
781-317-1938

• Exceeded profitability guidance for the quarter
• Generated record-high third quarter free cash flow from operations of $268M, and adjusted free cash flow of $218M
• Increased quarterly dividend

NEWARK, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, today announced financial results for the fiscal third quarter ended August 31, 2026.

	Three Months Ended
	August 31, 2026				August 31, 2025				Change
Revenue ($M)	$	2,453.7			$	2,483.3			(1.2	)%
Operating income (loss) ($M) (1)	$	(910.3	)		$	147.0			NM
Non-GAAP operating income ($M) (2)	$	309.0			$	305.1			1.3	%
Operating margin (1)	(37.1		)%			5.9	%		NM
Non-GAAP operating margin (2)		12.6	%			12.3	%		30 bps
Net income (loss) ($M) (1)	$	(988.1	)		$	88.1			NM
Non-GAAP net income ($M) (2)	$	186.5			$	183.2			1.8	%
Adjusted EBITDA ($M) (2)	$	363.0			$	359.2			1.1	%
Adjusted EBITDA margin (2)		14.8	%			14.5	%		30 bps
Diluted earnings (loss) per common share (1)	$	(16.24	)		$	1.34			NM
Non-GAAP diluted earnings per common share (2)	$	2.92			$	2.78			5.0	%

⁽¹⁾ Operating loss, operating margin, net loss and diluted loss per common share in the third quarter of 2026 include a non-cash goodwill impairment charge of $1,050.0 million primarily resulting from the trading range for the Company’s stock price and market capitalization.
⁽²⁾ See non-GAAP reconciliations included in the accompanying financial tables for the reconciliation of each non-GAAP measure to its most directly comparable GAAP measure.
NM Not Meaningful – Change greater than 100% or 1,000 bps.

Third Quarter Fiscal 2026 Highlights:

• Revenue of $2,453.7 million, a decrease of (1.2)% year-on-year on an as reported basis compared to revenue of $2,483.3 million in the prior year third quarter. The Company’s revenue decreased by (0.5)% year-on-year on a constant currency basis.
• Operating loss of $(910.3) million, or (37.1)% of revenue, compared to $147.0 million, or 5.9% of revenue, in the prior year third quarter. Operating loss for the quarter includes a non-cash goodwill impairment charge of $1,050.0 million primarily resulting from the recent trading range for the Company’s stock price and market capitalization.
• Non-GAAP operating income of $309.0 million, or 12.6% of revenue, compared with $305.1 million, or 12.3% of revenue in the prior year third quarter.
• Adjusted EBITDA of $363.0 million, or 14.8% of revenue, compared with $359.2 million, or 14.5% of revenue in the prior year third quarter.
• Cash flow provided by operations was $268.2 million in the quarter. Adjusted free cash flow⁽¹⁾ was $218.3 million in the quarter.
• Diluted earnings (loss) per common share (“EPS”) was $(16.24), inclusive of the goodwill impairment referenced above, compared to $1.34 in the prior year third quarter.
• Non-GAAP diluted EPS was $2.92 compared to $2.78 in the prior year third quarter.

“This quarter, we reached an inflection point where 50% of our revenue is coming from business we have won and deployed within the last 3 years since the introduction of AI,” said Chris Caldwell, President and CEO of Concentrix. “While we are aggressively disrupting our own traditional business, the underlying new business is stronger and healthier as evidenced by our margin expansion, strong free cash flow and growth of our new services.”

Quarterly Dividend and Share Repurchase Program:

• The Company paid a $0.36 per share quarterly dividend on August 4, 2026. The Company’s Board of Directors has declared a quarterly dividend of $0.37 per share payable on November 3, 2026, to shareholders of record at the close of business on October 23, 2026.
• The Company did not repurchase any shares under its share repurchase program during the third quarter of fiscal year 2026. At August 31, 2026, the Company’s remaining share repurchase authorization was $396.6 million.

Business Outlook:
The following statements are based on the Company’s current expectations for the fourth quarter and the full year fiscal 2026. Non-GAAP financial measures exclude the impact of impairment charge, acquisition-related, integration and restructuring expenses, amortization of intangible assets, depreciation, loss on held for sale, share-based compensation and the related tax effects thereon. The non-GAAP EPS guidance assumes no impact from changes in acquisition contingent consideration and foreign currency losses (gains), net included in other expense (income), net. These statements are forward-looking and actual results may differ materially.

Fourth Quarter Fiscal 2026 Expectations:

• Fourth quarter reported revenue of $2.410 billion to $2.460 billion. Based on current exchange rates, these expectations assume an approximate 65-basis point negative impact of foreign exchange rates compared with the prior year period. The guidance implies constant currency revenue decline for the quarter ranging from (5.0)% to (3.0)%.
• Operating income of $174 million to $184 million and non-GAAP operating income of $310 million to $320 million.
• Non-GAAP diluted EPS of $2.86 to $2.98, assuming approximately 61.2 million diluted common shares outstanding and approximately 4.9% of net income attributable to participating securities.
• The effective tax rate is expected to be approximately 24%.

Full Year 2026 Expectations:

• Full year reported revenue of $9.827 billion to $9.877 billion. Based on current exchange rates, these expectations assume an approximate 80-basis point positive impact of foreign exchange rates compared with the prior year. The guidance implies constant currency revenue decline for the full year of (0.8)% to (0.3)%.
• Operating loss of $(522) million to $(512) million and non-GAAP operating income of $1,206 million to $1,216 million.
• Non-GAAP diluted EPS of $10.97 to $11.09, assuming approximately 61.1 million diluted common shares outstanding and approximately 4.9% of net income attributable to participating securities.
• The effective tax rate is expected to be approximately 24%.

In addition, the Company expects to generate approximately $630.0 million to $650.0 million of adjusted free cash flow in fiscal year 2026.

The Company believes that a quantitative reconciliation of the non-GAAP EPS outlook to the most directly comparable GAAP measure cannot be provided without unreasonable efforts due to the inability to forecast future foreign currency losses (gains), net included in other expense (income), net. For the same reason, the Company is unable to address the probable significance of the unavailable information, which may have a material impact on the Company’s GAAP results.

The Company believes that a quantitative reconciliation of the adjusted free cash flow outlook to the most directly comparable GAAP measure cannot be provided without unreasonable efforts due to uncertainty related to the future changes in the Company’s factoring program and related timing of those changes. For the same reason, the Company is unable to address the probable significance of the unavailable information, which may have a material impact on the Company’s GAAP results.

Conference Call and Webcast
The Company will host a conference call for investors to review its third quarter fiscal 2026 results today at 5:00 p.m. (ET)/2:00 p.m. (PT).

The live conference call webcast will be available in listen-only mode in the Investor Relations section of the Company’s website under “Events and Presentations” at https://ir.concentrix.com/events-and-presentations. A replay will also be available on the website following the conference call.

About Concentrix: Powering a World That Works
Concentrix Corporation (NASDAQ: CNXC), is the Fortune 500® technology and services company, helping the world’s best brands create intelligent operations that perform in the real world. We design, build, and run integrated human and AI solutions, harnessing the insight from billions of real-world interactions to help 2,000+ of the world’s most complex organizations solve their toughest business challenges. Backed by 20+ years of operational experience and battle tested AI, we’re the intelligent transformation partner that helps clients across every major industry move from ambition to measurable, scalable performance. Virtually everywhere. To learn more, visit concentrix.com.

Use of Non-GAAP Information
In addition to disclosing financial results that are determined in accordance with GAAP, we also disclose certain non-GAAP financial information, including:

• Constant currency revenue growth (decline), which is revenue growth (decline) adjusted for the translation effect of foreign currencies so that certain financial results can be viewed without the impact of fluctuations in foreign currency exchange rates, thereby facilitating period-to-period comparisons of our business performance. Constant currency revenue growth (decline) is calculated by translating the revenue of each fiscal year in the billing currency to U.S. dollars using the comparable prior year’s currency conversion rate in comparison to prior year’s revenue. Generally, when the U.S. dollar either strengthens or weakens against other currencies, revenue growth at constant currency rates or adjusting for currency will be higher or lower than revenue growth reported at actual exchange rates.
• Non-GAAP operating income, which is operating income (loss), adjusted to exclude impairment charge, acquisition-related, integration and restructuring expenses, step-up depreciation, amortization of intangible assets, loss on held for sale and share-based compensation.
• Non-GAAP operating margin, which is non-GAAP operating income, as defined above, divided by revenue.
• Adjusted earnings before interest, taxes, depreciation, and amortization, or adjusted EBITDA, which is non-GAAP operating income, as defined above, plus depreciation (exclusive of step-up depreciation).
• Adjusted EBITDA margin, which is adjusted EBITDA, as defined above, divided by revenue.
• Non-GAAP net income, which is net income (loss) excluding the tax-effected impact of impairment charge, acquisition-related, integration and restructuring expenses, step-up depreciation, amortization of intangible assets, loss on held for sale, share-based compensation, certain debt costs, imputed interest related to the Sellers’ Note, certain legal settlement costs, change in acquisition contingent consideration and foreign currency losses (gains), net. Non-GAAP net income also excludes the income tax effect of certain tax law changes.
• Free cash flow, which is cash flows from operating activities less capital expenditures, and adjusted free cash flow, which is free cash flow excluding the effect of changes in the outstanding factoring balance. We believe that free cash flow is a meaningful measure of cash flows since capital expenditures are a necessary component of ongoing operations. We believe that adjusted free cash flow is a meaningful measure of cash flows because it removes the effect of factoring, which changes the timing of the receipt of cash for certain receivables. However, free cash flow and adjusted free cash flow have limitations because they do not represent the residual cash flow available for discretionary expenditures. For example, free cash flow and adjusted free cash flow do not incorporate payments for business acquisitions.
• Non-GAAP diluted EPS, which is diluted EPS excluding the per share, tax-effected impact of impairment charge, acquisition-related, integration and restructuring expenses, step-up depreciation, amortization of intangible assets, loss on held for sale, share-based compensation, certain debt costs, imputed interest related to the Sellers’ Note, certain legal settlement costs, change in acquisition contingent consideration and foreign currency losses (gains), net. Non-GAAP EPS also excludes the per share income tax effect of certain tax law changes. Non-GAAP EPS also reflects a per share adjustment to exclude non-GAAP net income attributable to participating securities.

We believe that providing this additional information is useful to the reader to better assess and understand our base operating performance, especially when comparing results with previous periods and for planning and forecasting in future periods, primarily because management typically monitors the business adjusted for these items in addition to GAAP results. Management also uses these non-GAAP measures to establish operational goals and, in some cases, for measuring performance for compensation purposes. These non-GAAP financial measures exclude amortization of intangible assets. Although intangible assets contribute to our revenue generation, the amortization of intangible assets does not directly relate to the services performed for our clients. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of our acquisition activity. Accordingly, we believe excluding the amortization of intangible assets, along with the other non-GAAP adjustments, which neither relate to the ordinary course of our business nor reflect our underlying business performance, enhances our and our investors’ ability to compare our past financial performance with our current performance and to analyze underlying business performance and trends. These non-GAAP financial measures also exclude share-based compensation expense. Given the subjective assumptions and the variety of award types that companies can use when calculating share-based compensation expense, management believes this additional information allows investors to make additional comparisons between our operating results and those of our peers. As these non-GAAP financial measures are not calculated in accordance with GAAP, they may not necessarily be comparable to similarly titled measures employed by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures and should be used as a complement to, and in conjunction with, data presented in accordance with GAAP.

Safe Harbor Statement
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding the Company’s expected future financial condition, growth and profitability, results of operations, including revenue and operating income, cash flows, and effective tax rate, leverage and liquidity, capital expenditures and anticipated investment costs, the Company’s stock price and market capitalization, the future growth and success of, and demand for, the Company’s services and products, the potential benefits associated with use of the Company’s artificial intelligence (“AI”) solutions and other products, share repurchase and dividend activity, capital allocation, debt repayment and obligations, business strategy, product launches, foreign currency exchange rate fluctuations, and statements that include words such as believe, expect, intend, plan, may, will, anticipate, provide, could, should, target, estimate, outlook, and other similar expressions. These forward-looking statements are inherently uncertain and involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things: risks related to general economic and geopolitical conditions and their effects on our clients’ businesses and demand for our services, including consumer demand, interest rates, inflation, the price of oil and other petroleum-based products, international tariffs and global trade policies, supply chains, and the conflicts in the Middle East and Ukraine; cyberattacks on the Company’s or its clients’ networks and information technology systems; uncertainty around, and disruption from, new and emerging technologies, including the adoption and utilization of AI, including agentic and generative AI; the failure of the Company’s staff and contractors to adhere to the Company’s and its clients’ controls and processes; the inability to protect personal and proprietary information; the effects of communicable diseases or other public health crises, natural disasters and adverse weather conditions; geopolitical, economic and climate- or weather-related risks in regions with a significant concentration of the Company’s operations; the ability to successfully execute the Company’s strategy; the timing and success of product launches; competitive conditions in the Company’s industry and consolidation of its competitors; variability in demand by the Company’s clients or the early termination of the Company’s client contracts; the level of business activity of the Company’s clients and the market acceptance and performance of their products and services; the demand for end-to-end solutions and technology; damage to the Company’s reputation through the actions or inactions of third parties; changes in law, regulations, or regulatory guidance, or changes in their interpretation or enforcement, including changes in law and policy that restrict offshoring or travel or visas between countries in which we have operations; the operability of the Company’s communication services and information technology systems and networks; the loss of key personnel or the inability to attract and retain staff across all geographies with the skills and expertise needed for the Company’s business; increases in the cost of labor, including minimum wage rates in the countries in which the Company operates; the inability to successfully identify, complete, and integrate strategic acquisitions or investments or realize anticipated benefits within the expected timeframe; higher than expected tax liabilities; currency exchange rate fluctuations; investigative or legal actions; and other factors contained in the Company’s Annual Report on Form 10-K for the fiscal year ended November 30, 2025 filed with the Securities and Exchange Commission (“SEC”) and subsequent documents filed with or furnished to the SEC. The Company does not undertake a duty to update forward-looking statements, which speak only as of the date on which they are made, except as required by law.

Copyright 2026 Concentrix Corporation. All rights reserved. Concentrix, the Concentrix logo, and all other Concentrix company, product, and services word and design marks and slogans are trademarks or registered trademarks of Concentrix Corporation and its subsidiaries. Other names and marks are the property of their respective owners.

From Fortune ©2026 Fortune Media (USA) Corporation. All rights reserved. Used under license. Fortune and Fortune 500 are registered trademarks of Fortune Media (USA) Corporation and are used under license. Fortune and Fortune Media (USA) Corporation are not affiliated with, and do not endorse products or services of, Concentrix.

Investor Contact:
Elise Brassell
Concentrix Corporation
Investor.relations@concentrix.com

CONCENTRIX CORPORATION CONSOLIDATED BALANCE SHEETS (currency and share amounts in thousands, except par value)
	August 31, 2026				November 30, 2025
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	244,692			$	327,347
Accounts receivable, net		1,969,848				1,999,021
Assets held for sale		212,959				—
Other current assets		489,238				758,135
Total current assets		2,916,737				3,084,503
Property and equipment, net		698,116				735,550
Operating lease right-of-use assets, net		864,749				857,025
Goodwill		2,636,667				3,671,746
Intangible assets, net		1,651,400				1,960,338
Deferred tax assets		346,058				317,453
Other assets		147,042				134,471
Total assets	$	9,260,769			$	10,761,086
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	221,495			$	244,771
Current portion of long-term debt		450,000				65,625
Accrued compensation and benefits		680,040				764,962
Other accrued liabilities		763,409				997,198
Income taxes payable		73,221				123,794
Liabilities held for sale		182,149				—
Total current liabilities		2,370,314				2,196,350
Long-term debt, net		3,925,373				4,572,889
Other long-term liabilities		949,867				950,983
Deferred tax liabilities		246,476				296,519
Total liabilities		7,492,030				8,016,741
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000 shares authorized and no shares issued and outstanding as of August 31, 2026 and November 30, 2025, respectively		—				—
Common stock, $0.0001 par value, 250,000 shares authorized; 70,679 and 70,316 shares issued as of August 31, 2026 and November 30, 2025, respectively, and 60,948 and 61,739 shares outstanding as of August 31, 2026 and November 30, 2025, respectively		7				7
Additional paid-in capital		3,859,842				3,783,972
Treasury stock, 9,731 and 8,577 shares as of August 31, 2026 and November 30, 2025, respectively		(657,424	)			(610,162	)
Retained deficit		(1,157,782	)			(177,010	)
Accumulated other comprehensive loss		(275,904	)			(252,462	)
Total stockholders’ equity		1,768,739				2,744,345
Total liabilities and stockholders’ equity	$	9,260,769			$	10,761,086

CONCENTRIX CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (currency and share amounts in thousands, except per share amounts) (unaudited)
	Three Months Ended											Nine Months Ended
	August 31, 2026				August 31, 2025				% Change			August 31, 2026				August 31, 2025				% Change
Revenue
Technology and consumer electronics	$	603,512			$	670,573			(10	)%		$	1,862,845			$	1,990,984			(6	)%
Retail, travel and e-commerce		662,612				622,822			6	%			1,952,770				1,790,502			9	%
Communications and media		381,905				411,229			(7	)%			1,168,176				1,175,192			(1	)%
Banking, financial services and insurance		432,463				384,449			12	%			1,286,456				1,133,657			13	%
Healthcare		145,173				174,106			(17	)%			475,872				540,297			(12	)%
Other		228,014				220,074			4	%			670,424				642,214			4	%
Total revenue	$	2,453,679			$	2,483,253			(1	)%		$	7,416,543			$	7,272,846			2	%
Cost of revenue		1,604,800				1,628,246			(1	)%			4,894,658				4,713,792			4	%
Gross profit		848,879				855,007			(1	)%			2,521,885				2,559,054			(1	)%
Selling, general and administrative expenses		709,184				708,023			—	%			2,168,210				2,094,858			4	%
Impairment charge		1,050,000				—			NM				1,050,000				—			NM
Operating income (loss)		(910,305	)			146,984			NM				(696,325	)			464,196			NM
Interest expense and finance charges, net		64,856				72,014			(10	)%			208,247				220,414			(6	)%
Other expense (income), net		4,603				(36,474	)		NM				(23,014	)			(20,175	)		14	%
Income (loss) before income taxes		(979,764	)			111,444			NM				(881,558	)			263,957			NM
Provision for income taxes		8,349				23,334			(64	)%			29,690				63,497			(53	)%
Net income (loss)	$	(988,113	)		$	88,110			NM			$	(911,248	)		$	200,460			NM
Earnings (loss) per common share:
Basic	$	(16.24	)		$	1.34						$	(14.99	)		$	3.01
Diluted	$	(16.24	)		$	1.34						$	(14.99	)		$	3.01
Weighted-average common shares outstanding:
Basic		60,910				62,598							61,011				63,325
Diluted		60,910				62,702							61,011				63,379

NM Not Meaningful – Change greater than 100%.

CONCENTRIX CORPORATION RECONCILIATION OF GAAP TO NON-GAAP MEASURES (currency and share amounts in thousands, except per share amounts) (unaudited)
	Three Months Ended				Nine Months Ended
	August 31, 2026				August 31, 2026
Revenue	$	2,453,679			$	7,416,543
Revenue growth (decline), as reported under U.S. GAAP	(1.2		)%			2.0	%
Foreign exchange impact		0.7	%		(1.3		)%
Constant currency revenue growth (decline)	(0.5		)%			0.7	%

	Three Months Ended								Nine Months Ended
	August 31, 2026				August 31, 2025				August 31, 2026				August 31, 2025
Operating income (loss)	$	(910,305	)		$	146,984			$	(696,325	)		$	464,196
Impairment charge		1,050,000				—				1,050,000				—
Acquisition-related, integration and restructuring expenses (1)		42,493				18,619				142,867				53,451
Step-up depreciation		2,626				2,704				8,082				7,616
Amortization of intangibles		100,908				111,779				306,421				326,556
Loss on held for sale		1,528				—				8,420				—
Share-based compensation		21,757				25,042				76,579				78,504
Non-GAAP operating income	$	309,007			$	305,128			$	896,044			$	930,323

	Three Months Ended								Nine Months Ended
	August 31, 2026				August 31, 2025				August 31, 2026				August 31, 2025
Net income (loss)	$	(988,113	)		$	88,110			$	(911,248	)		$	200,460
Interest expense and finance charges, net		64,856				72,014				208,247				220,414
Provision for income taxes		8,349				23,334				29,690				63,497
Other expense (income), net		4,603				(36,474	)			(23,014	)			(20,175	)
Impairment charge		1,050,000				—				1,050,000				—
Acquisition-related, integration and restructuring expenses (1)		42,493				18,619				142,867				53,451
Step-up depreciation		2,626				2,704				8,082				7,616
Amortization of intangibles		100,908				111,779				306,421				326,556
Loss on held for sale		1,528				—				8,420				—
Share-based compensation		21,757				25,042				76,579				78,504
Depreciation (exclusive of step-up depreciation)		53,947				54,074				162,466				160,410
Adjusted EBITDA	$	362,954			$	359,202			$	1,058,510			$	1,090,733

	Three Months Ended						Nine Months Ended
	August 31, 2026			August 31, 2025			August 31, 2026			August 31, 2025
Operating margin	(37.1	)%		5.9	%		(9.4	)%		6.4	%
Non-GAAP operating margin	12.6	%		12.3	%		12.1	%		12.8	%
Adjusted EBITDA margin	14.8	%		14.5	%		14.3	%		15.0	%

	Three Months Ended								Nine Months Ended
	August 31, 2026				August 31, 2025				August 31, 2026				August 31, 2025
Net income (loss)	$	(988,113	)		$	88,110			$	(911,248	)		$	200,460
Impairment charge		1,050,000				—				1,050,000				—
Acquisition-related, integration and restructuring expenses (1)		42,493				18,619				142,867				53,451
Step-up depreciation		2,626				2,704				8,082				7,616
Debt costs (2)		—				—				6,268				1,102
Imputed interest related to Sellers’ Note included in interest expense and finance charges, net		—				4,739				—				13,428
Legal settlement costs (3)		—				—				—				2,000
Change in acquisition contingent consideration included in other expense (income), net		2,125				(2,417	)			1,180				4,250
Foreign currency losses (gains), net (4)		(889	)			(35,531	)			(33,548	)			(28,921	)
Amortization of intangibles		100,908				111,779				306,421				326,556
Loss on held for sale		1,528				—				8,420				—
Share-based compensation		21,757				25,042				76,579				78,504
Income taxes related to the above (5)		(40,628	)			(30,535	)			(126,490	)			(112,458	)
Income tax effect of change in tax law		(5,298	)			721				(5,298	)			4,990
Non-GAAP net income	$	186,509			$	183,231			$	523,233			$	550,978

	Three Months Ended								Nine Months Ended
	August 31, 2026				August 31, 2025				August 31, 2026				August 31, 2025
Net income (loss)	$	(988,113	)		$	88,110			$	(911,248	)		$	200,460
Less: net income allocated to participating securities (6)		(1,116	)			(4,214	)			(3,461	)			(9,709	)
Net income (loss) attributable to common stockholders	$	(989,229	)		$	83,896			$	(914,709	)		$	190,751

	Three Months Ended								Nine Months Ended
	August 31, 2026				August 31, 2025				August 31, 2026				August 31, 2025
Non-GAAP net income	$	186,509			$	183,231			$	523,233			$	550,978
Less: Non-GAAP net income allocated to participating securities (7)		(8,929	)			(8,763	)			(25,651	)			(26,685	)
Non-GAAP income attributable to common stockholders	$	177,580			$	174,468			$	497,582			$	524,293

	Three Months Ended								Nine Months Ended
	August 31, 2026				August 31, 2025				August 31, 2026				August 31, 2025
Diluted earnings (loss) per common share (“EPS”) (6)	$	(16.24	)		$	1.34			$	(14.99	)		$	3.01
Impairment charge		17.24				—				17.21				—
Acquisition-related, integration and restructuring expenses		0.70				0.30				2.34				0.84
Step-up depreciation		0.04				0.04				0.13				0.12
Debt costs (2)		—				—				0.10				0.02
Imputed interest related to Sellers’ Note included in interest expense and finance charges, net		—				0.08				—				0.21
Legal settlement costs (3)		—				—				—				0.03
Change in acquisition contingent consideration included in other expense (income), net		0.03				(0.04	)			0.02				0.07
Foreign currency losses (gains), net (4)		(0.01	)			(0.57	)			(0.55	)			(0.46	)
Amortization of intangibles		1.66				1.78				5.02				5.15
Loss on held for sale		0.03				—				0.14				—
Share-based compensation		0.36				0.40				1.26				1.24
Income taxes related to the above (5)		(0.67	)			(0.49	)			(2.07	)			(1.77	)
Income tax effect of change in tax law		(0.09	)			0.01				(0.09	)			0.08
Adjustment for participating securities (7)		(0.13	)			(0.07	)			(0.36	)			(0.27	)
Non-GAAP Diluted EPS (7)	$	2.92			$	2.78			$	8.16			$	8.27
Weighted-average number of common shares – diluted		60,910				62,702				61,011				63,379

	Three Months Ended								Nine Months Ended
	August 31, 2026				August 31, 2025				August 31, 2026				August 31, 2025
Net cash provided by operating activities	$	268,206			$	224,803			$	442,878			$	462,747
Purchases of property and equipment		(46,978	)			(65,054	)			(149,054	)			(171,464	)
Free cash flow		221,228				159,749				293,824				291,283
Change in outstanding factoring balances		(2,911	)			19,056				22,205				47,992
Adjusted free cash flow	$	218,317			$	178,805			$	316,029			$	339,275

	Forecast
	Three Months Ending November 30, 2026								Fiscal Year Ending November 30, 2026
	Low				High				Low				High
Revenue	$	2,410,000			$	2,460,000			$	9,826,543			$	9,876,543
Revenue growth (decline), as reported under U.S. GAAP	(5.65		)%		(3.65		)%			—	%			0.50	%
Foreign exchange impact		0.65	%			0.65	%		(0.80		)%		(0.80		)%
Constant currency revenue decline	(5.00		)%		(3.00		)%		(0.80		)%		(0.30		)%

	Forecast
	Three Months Ending November 30, 2026								Fiscal Year Ending November 30, 2026
	Low				High				Low				High
Operating income (loss)	$	174,400			$	184,400			$	(521,925	)		$	(511,925	)
Impairment charge		—				—				1,050,000				1,050,000
Amortization of intangibles		85,000				85,000				391,421				391,421
Share-based compensation		19,700				19,700				96,279				96,279
Acquisition-related, integration and restructuring expenses		30,000				30,000				172,867				172,867
Step-up depreciation		900				900				8,982				8,982
Loss on held for sale		—				—				8,420				8,420
Non-GAAP operating income	$	310,000			$	320,000			$	1,206,044			$	1,216,044

⁽¹⁾ For the three and nine months ended August 31, 2026, acquisition-related, integration and restructuring expenses primarily included restructuring costs associated with our recent cost reduction initiatives, including severance and employee-related costs. Restructuring expenses also included costs associated with facilities consolidation, including lease terminations. For the three and nine months ended August 31, 2025, acquisition-related, integration and restructuring costs primarily included integration costs associated with our combination with Webhelp and restructuring expenses. These costs primarily included severance and employee-related costs, costs associated with facilities consolidation, including lease terminations to integrate the businesses, and information technology system consolidation costs.

⁽²⁾ For the nine months ended August 31, 2026, debt costs included debt extinguishment costs associated with our early redemption of $600 million of our senior notes due in August 2026. For the nine months ended August 31, 2025, debt costs included debt extinguishment costs associated with our restated credit agreement and our voluntary prepayment of a portion of our outstanding term loans.

⁽³⁾ For the nine months ended August 31, 2025, legal settlement costs consist of amounts incurred to settle certain litigation arising outside of the ordinary course of business.

⁽⁴⁾ Foreign currency losses (gains), net are included in other expense (income), net and primarily consist of gains and losses recognized on the revaluation and settlement of foreign currency transactions and realized and unrealized gains and losses on derivative contracts that do not qualify for hedge accounting.

⁽⁵⁾ The tax effect of taxable and deductible non-GAAP adjustments was calculated using the tax-deductible portion of the expenses and applying the entity-specific, statutory tax rates applicable to each item during the respective periods presented.

⁽⁶⁾ Diluted EPS is calculated using the two-class method, which is an earnings allocation proportional to the respective ownership among holders of common stock and participating securities. Restricted stock awards and certain restricted stock units granted to employees are considered participating securities. For the purposes of calculating diluted EPS for the three and nine months ended August 31, 2026, participating securities did not participate in net losses prior to dividends. For the purposes of calculating diluted EPS for the three and nine months ended August 31, 2025, net income attributable to participating securities was approximately 4.8%.

⁽⁷⁾ For the purposes of calculating non-GAAP net income attributable to common shareholders and non-GAAP diluted EPS, non-GAAP net income attributable to participating securities was approximately 4.8% and 4.8% of non-GAAP net income, respectively, for the three months ended August 31, 2026 and 2025, and 4.9% and 4.8% of non-GAAP net income, respectively, for the nine months ended August 31, 2026 and 2025, and was excluded from non-GAAP net income attributable to common shareholders to calculate non-GAAP diluted EPS.

NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option Award and RSU Award were each granted as of September 28, 2026 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

The option has a 10-year term and an exercise price of $7.51 per share, which is equal to the closing price per share of Arvinas’ common stock on the grant date. The Option Award will vest over four years, with 25% of the original number of shares underlying the Option Award vesting on the one-year anniversary of the employee’s start date and 1/48th of the original number of shares vesting monthly thereafter, and the RSU Award will vest in four equal installments on each one-year anniversary of the employee’s start date until the fourth anniversary of the start date, in each case subject to the employee’s continued service as an employee of, or other service provider to, Arvinas through the applicable vesting dates.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 101,600 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The Options were granted on September 25, 2026 and have an exercise price of $15.47 per share, which is equal to the closing price of Avalo’s common stock on the grant date. The Options will vest as to 25% of the underlying shares of common stock on the one-year anniversary of the applicable employee’s start date of employment, and the balance of the underlying shares of common stock vesting monthly thereafter over 36 months, subject to the applicable employee’s continued service relationship with Avalo through the applicable vesting dates. The Options are subject to the terms and conditions of Avalo’s 2025 Inducement Award Plan and award agreements thereunder.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries

Jonathan Neely
VP, Head of Investor Relations
jneely@avalotx.com 

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com 

Mechelen, Belgium; 29 September 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (“Lakefront”) announces that between September 21, 2026, and September 25, 2026, it has repurchased 106,060 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchase	Market/MTF	Number of shares	Average price paid (€)	Total (€)	Lowest price paid (€)	Highest price paid (€)
21/09/2026	XAMS	19,757	25.24	498,714.10	24.68	25.78
21/09/2026	TQEX	5	25.68	128.40	25.68	25.68
21/09/2026	AQEU	11	24.96	274.56	24.96	24.96
21/09/2026	CEUX	213	24.95	5,313.92	24.82	25.10
22/09/2026	XAMS	17,177	25.99	446,428.51	25.74	26.46
22/09/2026	TQEX	1,523	25.91	39,454.84	25.82	25.96
22/09/2026	AQEU	11	25.82	284.02	25.82	25.82
22/09/2026	CEUX	1,526	26.07	39,782.97	25.82	26.46
23/09/2026	XAMS	18,057	27.56	497,643.70	27.14	28.34
23/09/2026	TQEX	451	27.39	12,355.15	27.30	27.72
23/09/2026	AQEU	5	27.20	136.00	27.20	27.20
23/09/2026	CEUX	1,568	27.55	43,190.87	27.22	28.02
24/09/2026	XAMS	16,754	26.62	445,931.17	26.38	27.02
24/09/2026	TQEX	2,080	26.48	55,082.98	26.44	26.60
24/09/2026	AQEU	8	26.60	212.80	26.60	26.60
24/09/2026	CEUX	3,546	26.73	94,768.98	26.46	26.90
25/09/2026	XAMS	17,446	26.30	458,847.25	25.88	26.62
25/09/2026	TQEX	396	26.54	10,509.60	26.46	26.62
25/09/2026	AQEU	1,585	26.56	42,097.76	26.46	26.62
25/09/2026	CEUX	3,941	26.54	104,583.11	26.00	26.62
Total		106,060	26.36	2,795,740.67	24.68	28.34

As of market close on September 25, 2026, Lakefront holds 1,633,594 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Attachment

• 20260925 LakefrontEN RNS Announcement

SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it closed the sale of an additional 648,373 Class A ordinary shares of the Company, pursuant to the full exercise of the underwriter’s over-allotment option granted in connection with the Company’s public offering (“PO”, together with such over-allotment closing, the “Offering”), at a public offering price of $1.15 per share, for a total of approximately $745,629 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses. As a result, the Company has raised aggregate gross proceeds of approximately $5,716,491, including the previously announced PO gross proceeds of approximately $4,970,862, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

The Company intends to use net proceeds from the Offering for expansion into new businesses, R&D activities to expand its product offerings, growth and expansion into new markets, building brand awareness, investment in equipment and infrastructure, and working capital and general corporate purposes.

R. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney Westwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman Islands legal counsels to the Company, respectively, and Ellenoff Grossman & Schole LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.

The Offering is being conducted pursuant to the Company’s Registration Statement on Form F-1 (File No: 333-297299) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on September 15, 2026. The Offering is being made only by means of a prospectus. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. Copies of the final prospectus related to the Offering may be obtained, from R. F. Lafferty & Co., Inc., 40 Wall Street, Suite 3602, New York, NY 10005; (212) 293-9090, or by email at offerings@rflafferty.com. In addition, a copy of the final prospectus relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the infertility, medical waste recycling, and health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https://www.cuprina.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the gross proceeds of the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact

Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg